Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's.
Novartis says continuous monthly ianalumab cut Sjögren’s disease activity by 7.5 ESSDAI points at week 108. Read more here.
Shares raced through a buy zone but are range of an alternate entry.
Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low disease activity at Week 1081 Improvements in stimulated salivary flow were maintained in patients with baseline salivary flow >0.4mL/min continuing ianalumab1 Patients who switched from placebo to ianalumab monthly saw improvements across most efficacy outcomes, including an increase in low disease act
Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicinesFirst company to achieve No. 1 rank across all Technical Areas since Index began in 2008, achieving R&D score almost twice the sector averageRecognizes progress to expand care for cancer and heart disease, Coartem® Baby, and next-gen antimalarial KLU156 (ganaplacide/lumefantrine) Basel, November 10, 2026 – Novartis today announced the company has ranked first place in the 2026 Access to Medicine
LLY, NVS and BAYRY stand out as the pharma sector rebounds in 2026, supported by innovative drug pipelines, strong product demand and rising earnings estimates.
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
FDA says Zolgensma’s benefits still outweigh risks, but weighs action after nine tumour cases emerge among 6,000 treated infants.
Novartis (NVS) stock drops as the company faces fresh safety concerns over Zolgensma gene therapy after reports of tumors found in treated children. Read more here.
Operating margins are on track to hit 40% by 2029 as cost discipline accelerates alongside new drug launches.
Santander, Novartis and other companies say AI is beginning to boost revenue, cut costs or improve profitability as investors seek returns.
Anthropic's S-1 filing says Claude can accelerate drug discovery and biology research, making life sciences central to the AI company's IPO pitch.
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.